Short-chain fatty acid profile in patients undergoing maintenance hemodialysis

Close metadata

OBJECTIVE

To assess the profile of short-chain fatty acids (SCFAs) in stool and the content of key SCFA-producing bacteria in patients undergoing maintenance hemodialysis.

MATERIAL AND METHODS

This cross-sectional, single-center study included 30 patients with end-stage renal disease (ESRD) undergoing hemodialysis and 20 healthy participants in the control group. SCFA levels in stool samples were measured using gas-liquid chromatography. The composition of the gut microbiota was evaluated using reverse transcription polymerase chain reaction (RT-PCR).

RESULTS

Patients on hemodialysis showed a significant reduction in the levels of SCFAs (acetic, propionic, and butyric acids) and their isoacids compared to the control group. Additionally, a marked decrease in SCFA-producing bacteria (Bifidobacterium spp., Lactobacillus spp., Faecalibacterium prausnitzii, Eubacterium rectale, Blautia spp., Prevotella spp., Akkermansia muciniphila) was more frequently observed in the ESRD group. The reduction in SCFA levels and the disruption of their profile in dialysis patients were correlated with C-reactive protein levels.

CONCLUSION

Patients undergoing maintenance hemodialysis are characterized by a significant reduction in SCFA levels and a decrease in the abundance of SCFA-producing bacteria, which may be associated with the activation of systemic inflammatory responses.

Keywords:

short-chain fatty acids

hemodialysis

gut microbiota

systemic inflammation

end-stage renal disease

Authors:

Pyatchenkov M.O.

S.M. Kirov Military Medical Academy

ORCID: 0000-0002-5893-3191

Shcherbakov E.V.

S.M. Kirov Military Medical Academy

ORCID: 0000-0002-3045-1721

Trandina A.E.

Kirov Military Medical Academy

ORCID: 0000-0003-1875-1059

Glushakov R.I.

S.M. Kirov Military Medical Academy

ORCID: 0000-0002-0161-5977

Belskykh A.N.

Kirov Military Medical Academy

ORCID: 0000-0002-0421-3797

Received:

30.01.2024

Accepted:

29.09.2024

List of references:

Yudina YuV, Korsunsky AA, Aminova AI, Abdullaeva GD, Prodeus AP. Gut microbiota as a separate body system. Russian Journal of Evidence-Based Gastroenterology. 2019;8(4-5):36-43. (In Russ.). https://doi.org/10.17116/dokgastro2019804-05136
Kaibysheva VO, Zharova ME, Filimendikova KYu, Nikonov EL. Human Microbiome: age-related changes and functions. Russian Journal of Evidence-Based Gastroenterology. 2020;9(2):42-55. (In Russ.). https://doi.org/10.17116/dokgastro2020902142
Cong J, Zhou P, Zhang R. Intestinal Microbiota-Derived Short Chain Fatty Acids in Host Health and Disease. Nutrients. 2022; 14(9):1977. https://doi.org/10.3390/nu14091977
van der Hee B, Wells JM. Microbial Regulation of Host Physiology by Short-chain Fatty Acids. Trends in Microbiology. 2021;29(8):700-712. https://doi.org/10.1016/j.tim.2021.02.001
Li LZ, Tao SB, Ma L, Fu P. Roles of short-chain fatty acids in kidney diseases. Chinese Medical Journal. 2019;132(10):1228-1232. https://doi.org/10.1097/CM9.0000000000000228
Kaibysheva VO, Zharova ME, Filimendikova KYu, Nikonov EL. Diseases Associated with Disturbed Intestinal Microbiota. Doctor.Ru. 2021;20(4):40-45. (In Russ.). https://doi.org/10.31550/1727-2378-2021-20-4-40-45
Rauf A, Khalil AA, Rahman UU, Khalid A, Naz S, Shariati MA, Rebezov M, Urtecho EZ, de Albuquerque RDDG, Anwar S, Alamri A, Saini RK, Rengasamy KRR. Recent advances in the therapeutic application of short-chain fatty acids (SCFAs): An updated review. Critical Reviews in Food Science and Nutrition. 2022;62(22):6034-6054. https://doi.org/10.1080/10408398.2021.1895064
Wang S, Lv D, Jiang S, Jiang J, Liang M, Hou F, Chen Y. Quantitative reduction in short-chain fatty acids, especially butyrate, contributes to the progression of chronic kidney disease. Clinical Science. 2019;133(17):1857-1870. https://doi.org/10.1042/CS20190171
Wu IW, Gao SS, Chou HC, Yang HY, Chang LC, Kuo YL, Dinh MCV, Chung WH, Yang CW, Lai HC, Hsieh WP, Su SC. Integrative metagenomic and metabolomic analyses reveal severity-specific signatures of gut microbiota in chronic kidney disease. Theranostics. 2020;10(12):5398-5411. https://doi.org/10.7150/thno.41725
Al Khodor S, Shatat IF. Gut microbiome and kidney disease: a bidirectional relationship. Pediatric Nephrology. 2017;32(6):921-931. https://doi.org/10.1007/s00467-016-3392-7
Wong J, Piceno YM, DeSantis TZ, Pahl M, Andersen GL, Vaziri ND. Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. American Journal of Nephrology. 2014;39(3):230-237. https://doi.org/10.1159/000360010
Zhao J, Ning X, Liu B, Dong R, Bai M, Sun S. Specific alterations in gut microbiota in patients with chronic kidney disease: an updated systematic review. Renal Failure. 2021;43(1):102-112. https://doi.org/10.1080/0886022X.2020.1864404
Noce A, Marchetti M, Marrone G, Di Renzo L, Di Lauro M, Di Daniele F, Albanese M, Di Daniele N, De Lorenzo A. Link between gut microbiota dysbiosis and chronic kidney disease. European Review for Medical and Pharmacological Sciences. 2022;26(6): 2057-2074. https://doi.org/10.26355/eurrev_202203_28354
Shin Y, Han S, Kwon J, Ju S, Choi TG, Kang I, Kim SS. Roles of Short-Chain Fatty Acids in Inflammatory Bowel Disease. Nutrients. 2023;15(20):4466. https://doi.org/10.3390/nu15204466
Fu Y, Lyu J, Wang S. The role of intestinal microbes on intestinal barrier function and host immunity from a metabolite perspective. Frontiers in Immunology. 2023;14:1277102. https://doi.org/10.3389/fimmu.2023.1277102
He M, Wei W, Zhang Y, Xiang Z, Peng D, Kasimumali A, Rong S. Gut microbial metabolites SCFAs and chronic kidney disease. Journal of Translational Medicine. 2024;22(1):172. https://doi.org/10.1186/s12967-024-04974-6
Andrade-Oliveira V, Amano MT, Correa-Costa M, Castoldi A, Felizardo RJ, de Almeida DC, Bassi EJ, Moraes-Vieira PM, Hiyane MI, Rodas AC, Peron JP, Aguiar CF, Reis MA, Ribeiro WR, Valduga CJ, Curi R, Vinolo MA, Ferreira CM, Câmara NO. Gut Bacteria Products Prevent AKI Induced by Ischemia-Reperfusion. Journal of the American Society of Nephrology. 2015;26(8): 1877-1888. https://doi.org/10.1681/ASN.2014030288
Vaziri ND, Liu SM, Lau WL, Khazaeli M, Nazertehrani S, Farzaneh SH, Kieffer DA, Adams SH, Martin RJ. High amylose resistant starch diet ameliorates oxidative stress, inflammation, and progression of chronic kidney disease. PLoS One. 2014;9(12):e114881. https://doi.org/10.1371/journal.pone.0114881
Marzocco S, Fazeli G, Di Micco L, Autore G, Adesso S, Dal Piaz F, Heidland A, Di Iorio B. Supplementation of Short-Chain Fatty Acid, Sodium Propionate, in Patients on Maintenance Hemodialysis: Beneficial Effects on Inflammatory Parameters and Gut-Derived Uremic Toxins, A Pilot Study (PLAN Study). Journal of Clinical Medicine. 2018;7(10):315. https://doi.org/10.3390/jcm7100315
Ríos-Covián D, Ruas-Madiedo P, Margolles A, Gueimonde M, de Los Reyes-Gavilán CG, Salazar N. Intestinal Short Chain Fatty Acids and their Link with Diet and Human Health. Frontiers in Microbiology. 2016;7:185. https://doi.org/10.3389/fmicb.2016.00185
Krishnamurthy V, Wei G, Baird B, Murtaugh M, Chonchol M, Raphael K, Greene T, Beddhu S. High dietary fiber intake is associated with decreased inflammation and all-cause mortality in patients with chronic kidney disease. Kidney International. 2012;81(3):300-306. https://doi.org/10.1038/ki.2011.355
Kemp JA, Regis de Paiva B, Fragoso Dos Santos H, Emiliano de Jesus H, Craven H, Z Ijaz U, Alvarenga Borges N, G Shiels P, Mafra D. The Impact of Enriched Resistant Starch Type-2 Cookies on the Gut Microbiome in Hemodialysis Patients: A Randomized Controlled Trial. Molecular Nutrition and Food Research. 2021;65(19):e2100374. https://doi.org/10.1002/mnfr.202100374
Tao P, Ji J, Wang Q, Cui M, Cao M, Xu Y. The role and mechanism of gut microbiota-derived short-chain fatty in the prevention and treatment of diabetic kidney disease. Frontiers in Immunology. 2022;13:1080456. https://doi.org/10.3389/fimmu.2022.1080456
Wu IW, Lee CC, Hsu HJ, Sun CY, Chen YC, Yang KJ, Yang CW, Chung WH, Lai HC, Chang LC, Su SC. Compositional and Functional Adaptations of Intestinal Microbiota and Related Metabolites in CKD Patients Receiving Dietary Protein Restriction. Nutrients. 2020;12(9):2799. https://doi.org/10.3390/nu12092799
Liu C, Yang L, Wei W, Fu P. Efficacy of probiotics/synbiotics supplementation in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Nutrition. 2024;11:1434613. https://doi.org/10.3389/fnut.2024.1434613
Sanekommu H, Taj S, Mah Noor R, Umair Akmal M, Akhtar R, Hossain M, Asif A. Probiotics and Fecal Transplant: An Intervention in Delaying Chronic Kidney Disease Progression? Clinical Practice. 2023;13(4):881-888. https://doi.org/10.3390/clinpract13040080

Kurokawa Y, Honma Y, Sawaki A, Naito Y, Iwagami S, Komatsu Y, Takahashi T, Nishida T, Doi T. Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial. Annals of Oncology. 2022;33(9):959-967. https://doi.org/10.1016/j.annonc.2022.05.518

Du CY, Zhou Y, Song C, Wang YP, Jie ZG, He YL, Liang XB, Cao H, Yan ZS, Shi YQ. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: A prospective randomised trial in China. European Journal of Cancer. 2014;50(10):1772-1778. https://doi.org/10.1016/j.ejca.2014.03.280

McAuliffe JC, Hunt KK, Lazar AJ, Choi H, Qiao W, Thall P, Pollock RE, Benjamin RS, Trent JC. A Randomized, Phase II Study of Preoperative plus Postoperative Imatinib in GIST: Evidence of Rapid Radiographic Response and Temporal Induction of Tumor Cell Apoptosis. Annals of Surgical Oncology. 2009;16(4):910-919. https://doi.org/10.1245/s10434-008-0177-7

Corless CL, Ballman KV, Antonescu C, Blanke CD, Blackstein ME, Demetri GD, von Mehren M, Maki RG, Pisters PW, DeMatteo RP. Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001. Journal of Clinical Oncology. 2010;28(15 Suppl):10006-10006. https://doi.org/10.1200/jco.2010.28.15_suppl.10006

Cousin S. A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE). Accessed August 20, 2024. https://clinicaltrials.gov/study/NCT03475953#more-information

Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib. Accessed August 20, 2024. https://clinicaltrials.gov/study/NCT0440922

Cogent Biosciences. (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors. Accessed August 20, 2024. https://clinicaltrials.gov/ct2/show/NCT05208047

Matsumoto S, Takayama T, Wakatsuki K, Enomoto K, Tanaka T, Migita K, Takano M, Nakajima Y. An esophageal gastrointestinal stromal tumor with regional lymph node metastasis. Esophagus. 2010;7(2):115-118. https://doi.org/10.1007/s10388-010-0231-y

Koyanagi K, Nakagawa M, Ozawa S, Nagase T, Seishima R, Kanai T. Thoracoscopic enucleation for small-sized gastrointestinal stromal tumor of the esophagus: report of two cases. Esophagus. 2010;7(4):219-224. https://doi.org/10.1007/s10388-010-0243-7

Masuda T, Toh Y, Kabashima A, Aoki Y, Harimoto N, Ito S, Taomoto J, Ikeda O, Ohga T, Adachi E, Sakaguchi Y, Hirahashi M, Nishiyama K, Okamura T. Overt lymph node metastases from a gastrointestinal stromal tumor of the esophagus. Journal of Thoracic and Cardiovascular Surgery. 2007;134(3):810-811. https://doi.org/10.1016/j.jtcvs.2007.06.002

Kobayashi H, Kiguchi G, Miki A, Uryuhara K, Okada N, Kaihara S, Imai Y, Hosotani R. A case report of giant esophageal gastrointestinal stromal tumor surgically resected after preoperative imatinib treatment. Esophagus. 2011;8(2):119-124. https://doi.org/10.1007/s10388-011-0264-x

Sato H, Kanda T, Hirota S, Bamba T, Sakamoto K, Kosugi SI, Matsuki A, Mashima Y, Watanabe G, Hatakeyama K. Surgical resection of gastrointestinal stromal tumor of esophagus following preoperative imatinib treatment: a case report. Esophagus. 2010;7(1):65-69. https://doi.org/10.1007/s10388-009-0217-9

Miettinen M, Sobin LH, Lasota J. Gastrointestinal Stromal Tumors of the Stomach. American Journal of Surgical Pathology. 2005;29(1):52-68. https://doi.org/10.1097/01.pas.0000146010.92933

Luo Y, Wu Y, Chang X, Huang B, Luo D, Zhang J, Zhang P, Shi H, Fan J, Nie X. Identification of a novel FGFR2-KIAA1217 fusion in esophageal gastrointestinal stromal tumours: A case report. Frontiers in Oncology. 2022;12. https://doi.org/10.3389/fonc.2022.884814

Haller F, Moskalev EA, Faucz FR, Barthelmeß S, Wiemann S, Bieg M, Assie G, Bertherat J, Schaefer IM, Otto C, Rattenberry E, Maher ER, Ströbel P, Werner M, Carney JA, Hartmann A, Stratakis CA, Agaimy A. Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad. Endocrine-Related Cancer. 2014;21(4):567-577. https://doi.org/10.1530/ERC-14-0254

Zhang L, Smyrk TC, Young WF, Stratakis CA, Carney JA. Gastric Stromal Tumors in Carney Triad Are Different Clinically, Pathologically, and Behaviorally From Sporadic Gastric Gastrointestinal Stromal Tumors: Findings in 104 Cases. American Journal of Surgical Pathology. 2010;34(1):53-64. https://doi.org/10.1097/PAS.0b013e3181c20f4f

Ricci R, Martini M, Cenci T, Carbone A, Lanza P, Biondi A, Rindi G, Cassano A, Larghi A, Persiani R, Larocca LM. PDGFRA-mutant syndrome. Modern Pathology. 2015;28(7):954-964. https://doi.org/10.1038/modpathol.2015.56

Arita A, Takahashi T, Nakajima K, Kurokawa Y, Hirota S, Nishida T, Yamashita K, Saito T, Tanaka K, Makino T, Yamasaki M, Kawai K, Motoyama Y, Morii E, Eguchi H, Doki Y. Surgery for multiple gastric gastrointestinal stromal tumors and large esophageal diverticulum related to germline mutation of the KIT gene: a case report. Surgical Case Reports. 2023;9(1):183. https://doi.org/10.1186/s40792-023-01766-w

Bachet JB, Landi B, Laurent-Puig P, Italiano A, Le Cesne A, Lévy P, Safar V, Duffaud F, Blay JY, Emile JF. Diagnosis, prognosis and treatment of patients with gastrointestinal stromal tumour (GIST) and germline mutation of KIT exon 13. European Journal of Cancer. 2013;49(11):2531-2541. https://doi.org/10.1016/j.ejca.2013.04.005

Ohshima K, Fujiya K, Nagashima T, Ohnami S, Hatakeyama K, Urakami K, Naruoka A, Watanabe Y, Moromizato S, Shimoda Y, Ohnami S, Serizawa M, Akiyama Y, Kusuhara M, Mochizuki T, Sugino T, Shiomi A, Tsubosa Y, Uesaka K, Terashima M, Yamaguchi K. Driver gene alterations and activated signaling pathways toward malignant progression of gastrointestinal stromal tumors. Cancer Science. 2019;110(12):3821-3833. https://doi.org/10.1111/cas.14202

Joensuu H, Eriksson M, Hall KS, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Ballman KV, Leinonen M, DeMatteo RP, Reichardt P. Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib. Cancer. 2014;120(15):2325-2333. https://doi.org/10.1002/cncr.28669

Rubió-Casadevall J, Borràs JL, Carmona-García MC, Ameijide A, Gonzalez-Vidal A, Ortiz MR, Bosch R, Riu F, Parada D, Martí E, Miró J, Sirvent JJ, Galceran J, Marcos-Gragera R. Correlation between mutational status and survival and second cancer risk assessment in patients with gastrointestinal stromal tumors: a population-based study. World Journal of Surgical Oncology. 2015;13(1):47. https://doi.org/10.1186/s12957-015-0474-0

Joensuu H, Rutkowski P, Nishida T, Steigen SE, Brabec P, Plank L, Nilsson B, Braconi C, Bordoni A, Magnusson MK, Sufliarsky J, Federico M, Jonasson JG, Hostein I, Bringuier PP, Emile JF. KIT and PDGFRA Mutations and the Risk of GI Stromal Tumor Recurrence. Journal of Clinical Oncology. 2015;33(6):634-642. https://doi.org/10.1200/JCO.2014.57.4970

Park JW, Cho CH, Jeong DS, Chae HD. Role of 18F-fluoro-2-deoxyglucose Positron Emission Tomography in Gastric GIST: Predicting Malignant Potential Pre-operatively. Journal of Gastric Cancer. 2011;11(3):173-179. https://doi.org/10.5230/jgc.2011.11.3.173

Dendy M, Johnson K, Boffa DJ. Spectrum of FDG uptake in large (>10 cm) esophageal leiomyomas. Journal of Thoracic Disease. 2015;7(12):E648-E651. https://doi.org/10.3978/j.issn.2072-1439.2015.11.64

Săftoiu A. Endoscopic ultrasound-guided fine needle aspiration biopsy for the molecular diagnosis of gastrointestinal stromal tumors: shifting treatment options. Journal of Gastrointestinal and Liver Diseases. 2008;17(2):131-133.

Lott S, Schmieder M, Mayer B, Henne-Bruns D, Knippschild U, Agaimy A, Schwab M, Kramer K. Gastrointestinal stromal tumors of the esophagus: evaluation of a pooled case series regarding clinicopathological features and clinical outcome. American Journal of Cancer Research. 2015;5(1):333-343.

Stelow EB, Stanley MW, Lai R, Mallery S. Endoscopic Ultrasound-Guided Fine-Needle Aspiration Findings of Gastrointestinal Leiomyomas and Gastrointestinal Stromal Tumors. American Journal of Clinical Pathology. 2003;119(5):703-708. https://doi.org/10.1309/UWUV-Q001-0D9W-0HPN

Nemeth K, Williams C, Rashid M, Robinson M, Rasheed A. Oesophageal GIST—A rare breed case report and review of the literature. International Journal of Surgery Case Reports. 2015;10: 256-259. https://doi.org/10.1016/j.ijscr.2015.02.023

Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology. 2008;53(3):245-266. https://doi.org/10.1111/j.1365-2559.2008.02977.x

Gold JS, Gönen M, Gutiérrez A, Broto JM, García-del-Muro X, Smyrk TC, Maki RG, Singer S, Brennan MF, Antonescu CR, Donohue JH, DeMatteo RP. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. The Lancet Oncology. 2009;10(11):1045-1052. https://doi.org/10.1016/S1470-2045(09)70242-6

Wozniak A, Rutkowski P, Piskorz A, Ciwoniuk M, Osuch C, Bylina E, Sygut J, Chosia M, Rys J, Urbanczyk K, Kruszewski W, Sowa P, Siedlecki J, Debiec-Rychter M, Limon J; Polish Clinical GIST Registry. Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience. Annals of Oncology. 2012;23(2):353-360. https://doi.org/10.1093/annonc/mdr127

Yamamoto H, Ebihara Y, Tanaka K, Matsui A, Nakanishi Y, Asano T, Noji T, Kurashima Y, Murakami S, Nakamura T, Tsuchikawa T, Okamura K, Shichinohe T, Hirano S. Robot-assisted thoracoscopic esophagectomy for gastrointestinal stromal tumor of the esophagus: A case report. International Journal of Surgery Case Reports. 2021;86:106335. https://doi.org/10.1016/j.ijscr.2021.106335

Marqueen KE, Moshier E, Buckstein M, Ang C. Neoadjuvant therapy for gastrointestinal stromal tumors: A propensity score‐weighted analysis. International Journal of Cancer. 2021;149(1):177-185. https://doi.org/10.1002/ijc.33536

Wang D, Zhang Q, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M, Eisenberg BL. Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132. Annals of Surgical Oncology. 2012;19(4):1074-1080. https://doi.org/10.1245/s10434-011-2190-5

Nishida T, Kanda T, Nishitani A, Takahashi T, Nakajima K, Ishikawa T, Hirota S. Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib‐resistant gastrointestinal stromal tumor. Cancer Science. 2008;99(4):799-804. https://doi.org/10.1111/j.1349-7006.2008.00727.x

Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, Leversha MA, Jeffrey PD, Desantis D, Singer S, Brennan MF, Maki RG, DeMatteo RP. Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation. Clinical Cancer Research. 2005;11(11):4182-4190. https://doi.org/10.1158/1078-0432.CCR-04-2245

See full prescribing information for VITRAKVI. Accessed September 10, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211710s000lbl.pdf

US Food and Drug Administration. Prescribing information — Rozlytrek. Accessed September 10, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf

Yebra M, Bhargava S, Kumar A, Burgoyne AM, Tang CM, Yoon H, Banerjee S, Aguilera J, Cordes T, Sheth V, Noh S, Ustoy R, Li S, Advani SJ, Corless CL, Heinrich MC, Kurzrock R, Lippman SM, Fanta PT, Harismendy O, Metallo C, Sicklick JK. Establishment of Patient-Derived Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response. Clinical Cancer Research. 2022;28(1):187-200. https://doi.org/10.1158/1078-0432.CCR-21-2092

Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST). Accessed September 10, 2024. https://clinicaltrials.gov/study/NCT03556384

Dhillon S. Ripretinib: First Approval. Drugs. 2020;80(11):1133-1138. https://doi.org/10.1007/s40265-020-01348-2

See full prescribing information for QINLOCK. Accessed September 10, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf

US Food and Drug Administration. FDA approves avapritinib for gastrointestinal stromal tumor with a rare mutation. Accessed September 10, 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avapritinib-gastrointestinal-stromal-tumor-rare-mutation

Chi P, Qin LX, Nguyen B, Kelly CM, D’Angelo SP, Dickson MA, Gounder MM, Keohan ML, Movva S, Nacev BA, Rosenbaum E, Thornton KA, Crago AM, Yoon S, Ulaner G, Yeh R, Martindale M, Phelan HT, Biniakewitz MD, Warda S, Lee CJ, Berger MF, Schultz ND, Singer S, Hwang S, Chen Y, Antonescu CR, Tap WD. Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor. Journal of Clinical Oncology. 2022;40(9):997-1008. https://doi.org/10.1200/JCO.21.02029

US National Library of Medicine. A study of pimitespib in combination with imatinib in patients with GIST (CHAPTER-GIST-101). Accessed September 10, 2024. https://www.clinicaltrials.gov/ct2/show/NCT05245968

Joensuu H, Blay JY, Comandone A, Martin-Broto J, Fumagalli E, Grignani G, Del Muro XG, Adenis A, Valverde C, Pousa AL, Bouché O, Italiano A, Bauer S, Barone C, Weiss C, Crippa S, Camozzi M, Castellana R, Le Cesne A. Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib. British Journal of Cancer. 2017;117(9):1278-1285. https://doi.org/10.1038/bjc.2017.290

Adis insight. Gastrointestinal stromal tumours. Accessed September 10, 2024. https://adisinsight.springer.com/drugs/800063657

US National Library of Medicine. A phase I/II study of regorafenib plus avelumab in solid tumors (REGOMUNE). Accessed September 10, 2024. https://clinicaltrials.gov/ct2/show/NCT03475953

US National Library of Medicine. PDR001 plus imatinib for metastatic or unresectable GIST. Accessed September 10, 2024. https://clinicaltrials.gov/ct2/show/NCT03609424

Call J, Walentas C, Eickhoff JC, Scherzer N. Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry. BMC Cancer. 2012;12(1):90. https://doi.org/10.1186/1471-2407-12-90

Miettinen M, Lasota J. Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Seminars in Diagnostic Pathology. 2006;23(2):70-83. https://doi.org/10.1053/j.semdp.2006.09.001

IJzerman NS, van Werkhoven E, Mohammadi M, Hollander DD, Bleckman RF, Reyners AKL, Desar IME, Gelderblom H, Grünhagen DJ, Mathijssen RHJ, Steeghs N, van der Graaf WTA. Sex differences in patients with gastrointestinal stromal tumours: do they exist and does it affect survival? ESMO Open. 2022;7(6):100649. https://doi.org/10.1016/j.esmoop.2022.100649

Volchenko NS, Mamontov AS, Goeva NS. Rare esophageal tumors. Onkologiya. P.A. Herzen Journal of Oncology. 2019;8(6):453. https://doi.org/10.17116/onkolog20198061453

Cohen C, Pop D, Icard P, Berthet JP, Venissac N, Mouroux J. Is There a Place for Thoracoscopic Enucleation of Esophageal Gastrointestinal Stromal Tumors? The Thoracic and Cardiovascular Surgeon. 2019;67(07):585-588. https://doi.org/10.1055/s-0038-1670662

Keung EZ, Raut CP. Management of Gastrointestinal Stromal Tumors. Surgical Clinics of North America. 2017;97(2):437-452. https://doi.org/10.1016/j.suc.2016.12.001

Gronchi A, Raut CP. The Combination of Surgery and Imatinib in GIST: A Reality for Localized Tumors at High Risk, an Open Issue for Metastatic Ones. Annals of Surgical Oncology. 2012;19(4): 1051-1055. https://doi.org/10.1245/s10434-011-2191-4

Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, Fletcher CD, Demetri GD, Bertagnolli MM. Surgical Management of Advanced Gastrointestinal Stromal Tumors After Treatment With Targeted Systemic Therapy Using Kinase Inhibitors. Journal of Clinical Oncology. 2006;24(15):2325-2331. https://doi.org/10.1200/JCO.2005.05.3439

Blackstein ME, Blay JY, Corless C, Driman DK, Riddell R, Soulières D, Swallow CJ, Verma S; Canadian Advisory Committee on GIST. Gastrointestinal Stromal Tumours: Consensus Statement on Diagnosis and Treatment. Canadian Journal of Gastroenterology. 2006;20(3):157-163. https://doi.org/10.1155/2006/434761

DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF, Antonescu CR. Results of Tyrosine Kinase Inhibitor Therapy Followed by Surgical Resection for Metastatic Gastrointestinal Stromal Tumor. Annals of Surgery. 2007;245(3):347-352. https://doi.org/10.1097/01.sla.0000236630.93587.59

Klug LR, Khosroyani HM, Kent JD, Heinrich MC. New treatment strategies for advanced-stage gastrointestinal stromal tumours. Nature Reviews Clinical Oncology. 2022;19(5):328-341. https://doi.org/10.1038/s41571-022-00606-4

A phase 1, multicenter, open-label, first-in-human study of DS-6157a in patients (pts) with advanced gastrointestinal stromal tumor (GIST). Accessed September 10, 2024. https://meetings.asco.org/abstracts-presentations/208008

DS-6157a in Participants with Advanced Gastrointestinal Stromal Tumor (GIST). Accessed September 10, 2024. https://clinicaltrials.gov/ct2/show/NCT04276415

Close metadata